These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1079 related articles for article (PubMed ID: 15726516)

  • 1. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
    Thorstad WL; Haughey B; Chao KS
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):96-100. PubMed ID: 14727249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
    Vacha P; Marx M; Engel A; Richter E; Feyerabend T
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
    Bourhis J; Rosine D
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
    de Castro G; Federico MH
    Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life.
    Eisbruch A; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Anzai Y; Marsh LH; Martel MK; Ten Haken RK; Wolf GT; Ship JA
    Acta Otorhinolaryngol Belg; 1999; 53(3):271-5. PubMed ID: 10635407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy-induced salivary dysfunction.
    Ship JA; Hu K
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):29-36. PubMed ID: 15726520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma.
    Daly ME; Lieskovsky Y; Pawlicki T; Yau J; Pinto H; Kaplan M; Fee WE; Koong A; Goffinet DR; Xing L; Le QT
    Head Neck; 2007 Mar; 29(3):211-20. PubMed ID: 17111429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?
    Jellema AP; Doornaert P; Slotman BJ; Leemans CR; Langendijk JA
    Radiother Oncol; 2005 Nov; 77(2):164-71. PubMed ID: 16256229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
    Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
    Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
    J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer.
    Saarilahti K; Kouri M; Collan J; Kangasmäki A; Atula T; Joensuu H; Tenhunen M
    Radiother Oncol; 2006 Mar; 78(3):270-5. PubMed ID: 16564589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
    Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.